OncoLab, developer of the immuno-oncology platform ANGel (ANtibody-conjugated microGel), announced on November 11 that it has raised 1 billion KRW ($688,000) in Pre-Series A funding from FuturePlay. The company will use the proceeds to prepare for global clinical trials through GLP non-clinical studies and GMP facility expansion.

OncoLab is developing a precision drug delivery system (DDS) platform based on highly biocompatible microgels that enable localized, sustained release of small-molecule anticancer agents directly within tumors. This approach minimizes systemic toxicity while maximizing therapeutic efficacy.

The company’s core technology, the ANGel platform, represents a next-generation immunotherapy that combines multiple antibodies and anticancer drugs within a single microparticle to simultaneously achieve cancer cell recognition, immune activation, and drug release. Antibodies on the particle surface precisely target cancer cells and amplify immune responses, while anticancer agents encapsulated inside are gradually released in the tumor microenvironment to eliminate cancer cells. This dual mechanism extends therapeutic effects while reducing side effects, addressing key limitations of conventional cancer treatments.

OncoLab is initially developing the platform for triple-negative breast cancer (TNBC), with plans to expand to other solid tumors including prostate cancer and non-small cell lung cancer through modular antibody combinations. The company is currently conducting GLP toxicity studies and humanized mouse efficacy trials, targeting an IND submission in 2026 as it accelerates toward global clinical development.

Som Kim, Principal at FuturePlay who led the investment, commented, “OncoLab has developed a highly refined next-generation platform that combines precision drug delivery with immuno-oncology, demonstrating both strong technical maturity and significant clinical scalability. We’re excited to support OncoLab’s innovative therapeutic development journey and look forward to achieving global technology licensing milestones together.”

Jong-seong Kim, CEO of OncoLab, explained, “The ANGel platform integrates antibodies and anticancer drugs within a single particle to directly attack cancer cells while simultaneously activating immune responses.” He added, “Beyond simply recombining existing drugs, we’re creating a platform that establishes a new paradigm for combination therapy, opening up novel treatment opportunities for more patients.”